ME02101B - Pročišćavanje antitijela hromatografijom izmjene katjona - Google Patents
Pročišćavanje antitijela hromatografijom izmjene katjonaInfo
- Publication number
- ME02101B ME02101B MEP-2015-34A MEP3415A ME02101B ME 02101 B ME02101 B ME 02101B ME P3415 A MEP3415 A ME P3415A ME 02101 B ME02101 B ME 02101B
- Authority
- ME
- Montenegro
- Prior art keywords
- cation exchange
- antibody
- exchange material
- washing
- buffer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (15)
1. Postupak za pročišćavanje antitela iz sastava koji sadrži antitelo i najmanje jedan zagađivač, gde postupak obuhvata sledeće uzastopne korake:a)nanošenje sastava na materijal izmene katjona, gde je sastav na početku na pH od 4,0 do 6,0;b)ispiranje materijala izmene katjona prvim puferom za ispiranje, gde je pH prvog pufera za ispiranje od 6,8 do 9,0;c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; id)eluciju antitela iz materijala izmene katjona puferom za eluciju na provodnosti koja je najmanje 2 mS/cm veća od one kod drugog pufera za ispiranje.
2. Postupak prema patentnom zahtevu 1 gde su pH drugog pufera za ispiranje i pH pufera za eluciju približno isti.
3. Postupak prema patentnom zahtevu 1 gde se antitelo vezuje na humani CD20.
4. Postupak prema patentnom zahtevu 1 gde se antitelo vezuje na humani vaskularni endotelni faktor rasta (VEGF).
5. Postupak prema patentnom zahtevu 1 gde je pH sastava kod (a) od 4,0 do 6,0, pH prvog pufera za ispiranje je od 6,8 do 8,0, pH drugog pufera za ispiranje od 5,0 do 6.0, a pH pufera za eluciju je od 5,0 do 6,0.
6. Postupak prema patentnom zahtevu 1 gde je provodnost pufera za eluciju od 10 mS/cm do 100 mS/cm.
7. Postupak prema patentnom zahtevu 1 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
8. Postupak prema patentnom zahtevu 1, gde materijal izmene katjona sadrži unakrsno spojene poli(stiren-divinilbenzen) protočne čestice obložene polihidroksiliranim polimerom koji je funkcionalizovan sulfopropil grupama.
9. Postupak prema patentnom zahtevu 1 gde je zagađivač odabran iz grupe koja se sastoji od proteina jajnih ćelija kineskog hrčka (CHOP), izlučenog proteina A, DNK, nagomilanih antitela, komponente medijuma ćelijske kulture, garamicina i virusnih zagađenja.
10. Postupak za pročišćavanje antitela koje vezuje humani CD20 iz sastava koji sadrži antitelo i jedan ili više zagađivač odabranih iz skupine koja se sastoji od proteina jajnih ćelija kineskog hrčka (CHOP), ispranog proteina A, DNK, nagomilanoih CD20 antitela, gde postupak obuhvata sledeće uzastopne korake: a)nanošenje sastava na materijal izmene katjona, gde je sastav na pH od 4,0 do 6,0; b)ispiranje materijala izmene katjona prvom puferom za ispiranje na 6,8 do 9,0; c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; i d)eluciju antitela iz materijala izmene katjona puferom za eluciju sa ph od 5,0 do 6,0 i provodnosti od 10 mS/cm do 100 mS/cm.
11. Postupak prema patentnom zahtevu 10 gde je antitelo rituksimab.
12. Postupak prema patentnom zahtevu 10 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
13. Postupak za pročišćavanje antitela koje vezuje humani vaskularni endotelni faktor rasta (VEGF) iz sastava koji sadrži antitelo i jedan ili više zagađivača odabranih iz grupe koja se sastoji od komponente medijuma ćelijske kulture, garamicina, proteina jajnih ćelija kineskog hrčka (CHOPS) DNK, virusnih zagađivača i nagomilanih VEGF antitela, gde postupak obuhvata sledeće uzastopne korake: a)nanošenje sastava na materijal izmene katjona, gde je sastav na pH od 4,0 do 6,0; b)ispiranje materijala izmene katjona prvom puferom za ispiranje na 6,8 do 8,0; c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; i d)eluciju antitela iz materijala izmene katjona puferom za eluciju sa ph od 5,0 do 6,0 i provodnosti od 10 mS/cm do 100 mS/cm.
14. Postupak prema patentnom zahtevu 13 gde je antitelo bevacizumab.
15. Postupak prema patentnom zahtevu 13 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98382507P | 2007-10-30 | 2007-10-30 | |
| EP08844379.1A EP2215117B2 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
| PCT/US2008/081516 WO2009058812A1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02101B true ME02101B (me) | 2015-10-20 |
Family
ID=40262967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-34A ME02101B (me) | 2007-10-30 | 2008-10-29 | Pročišćavanje antitijela hromatografijom izmjene katjona |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20090148435A1 (me) |
| EP (4) | EP2215117B2 (me) |
| JP (5) | JP5237382B2 (me) |
| KR (3) | KR101241486B1 (me) |
| CN (3) | CN101889025B (me) |
| AR (2) | AR069097A1 (me) |
| AU (1) | AU2008318865B2 (me) |
| BR (1) | BRPI0817182A2 (me) |
| CA (1) | CA2703279C (me) |
| CL (1) | CL2008003218A1 (me) |
| CO (1) | CO6280422A2 (me) |
| CY (1) | CY1116129T1 (me) |
| DK (3) | DK2565206T3 (me) |
| ES (3) | ES2572958T3 (me) |
| HK (1) | HK1221234A1 (me) |
| HR (2) | HRP20150282T4 (me) |
| HU (3) | HUE024877T2 (me) |
| IL (4) | IL205310A0 (me) |
| ME (1) | ME02101B (me) |
| MX (1) | MX2010004740A (me) |
| NZ (1) | NZ584839A (me) |
| PE (1) | PE20091434A1 (me) |
| PH (1) | PH12013501128A1 (me) |
| PL (3) | PL2840090T3 (me) |
| PT (1) | PT2215117E (me) |
| RS (1) | RS53850B2 (me) |
| RU (1) | RU2498991C2 (me) |
| SG (2) | SG10201401690XA (me) |
| SI (3) | SI2840090T1 (me) |
| TW (2) | TWI554517B (me) |
| WO (1) | WO2009058812A1 (me) |
| ZA (2) | ZA201002850B (me) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042914T2 (hu) | 2003-11-05 | 2019-07-29 | Roche Glycart Ag | CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
| EP3195879A1 (en) | 2005-02-23 | 2017-07-26 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| CA2842964A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| PL2840090T3 (pl) | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010048192A2 (en) * | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Viral inactivation during purification of antibodies |
| RU2520838C2 (ru) | 2008-10-20 | 2014-06-27 | Эббви Инк | Выделение и очистка антител с использованием аффинной хроматографии на основе белка а |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2011037983A1 (en) * | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Cation exchange chromatography |
| RU2012140447A (ru) * | 2010-02-23 | 2014-03-27 | Дженентек, Инк. | Антиангиогенная терапия для лечения рака яичника |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| AU2011235232B2 (en) * | 2010-03-30 | 2015-05-21 | Janssen Biotech Inc. | Humanized IL-25 antibodies |
| DK3333265T3 (da) | 2010-05-14 | 2020-04-27 | Univ Oregon Health & Science | Rekombinante hcmv- og rhcmv-vektorer der koder for et heterologt antigen isoleret fra hepatitis b-virus og anvendelser deraf |
| CN107365346A (zh) * | 2010-05-25 | 2017-11-21 | 弗·哈夫曼-拉罗切有限公司 | 纯化多肽的方法 |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| KR101574864B1 (ko) * | 2010-12-21 | 2015-12-11 | 에프. 호프만-라 로슈 아게 | 이소폼이 농축된 항체 제제 및 그의 제조 방법 |
| AU2012236486B2 (en) * | 2011-03-29 | 2016-06-23 | Glaxosmithkline Llc | Buffer system for protein purification |
| WO2012160530A1 (en) * | 2011-05-26 | 2012-11-29 | Dr. Reddy's Laboratories Limited | Purification of antibodies |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
| ES3023516T3 (en) | 2011-10-14 | 2025-06-02 | Hoffmann La Roche | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
| RU2648999C2 (ru) | 2011-12-22 | 2018-03-29 | Дженентек, Инк. | Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии |
| DK3495387T3 (da) | 2012-07-13 | 2021-11-08 | Roche Glycart Ag | Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme |
| EP2889617B1 (en) * | 2012-08-27 | 2017-10-11 | Asahi Kasei Medical Co., Ltd. | Antibody purification method by means of temperature-responsive chromatography |
| CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
| CA2902854C (en) * | 2013-03-08 | 2024-01-23 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
| UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| CA2907776C (en) | 2013-04-16 | 2020-04-14 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
| WO2015064971A1 (ko) * | 2013-10-30 | 2015-05-07 | (주)셀트리온 | 양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법 |
| CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业（上海）股份有限公司 | 重组蛋白质的纯化方法 |
| AU2014352824B2 (en) | 2013-11-25 | 2019-07-18 | Seagen Inc. | Preparing antibodies from CHO cell cultures for conjugation |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
| WO2015120056A1 (en) * | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| US10487138B2 (en) | 2014-03-10 | 2019-11-26 | Richter Gedeon Nyrt. | Immunoglobulin purification using pre-cleaning steps |
| CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| BR112017000696B1 (pt) | 2014-07-16 | 2023-10-03 | Oregon Health & Science University | Polinucleotídeo isolado |
| CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
| WO2016149088A1 (en) * | 2015-03-13 | 2016-09-22 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
| HRP20241134T1 (hr) | 2015-05-30 | 2024-11-22 | F. Hoffmann-La Roche Ag | Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke |
| KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN116926128A (zh) | 2015-11-20 | 2023-10-24 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| GB201600512D0 (en) | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
| MA44873A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
| US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| AU2017295037B2 (en) * | 2016-07-15 | 2021-07-22 | F. Hoffmann-La Roche Ag | Method for purifying PEGylated erythropoietin |
| CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
| WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
| CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
| CR20190205A (es) | 2016-10-18 | 2020-01-07 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan células t restringidas por moléculas del complejo mayor de histocompatibilidad e |
| WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
| CA3046092A1 (en) | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| CN117752782A (zh) | 2017-01-17 | 2024-03-26 | 豪夫迈·罗氏有限公司 | 皮下her2抗体配制剂 |
| KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| BE1025090B1 (fr) | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
| WO2018190677A2 (en) * | 2017-04-14 | 2018-10-18 | Cj Healthcare Corporation | Method for purifying analogous antibody using cation-exchange chromatography |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| US11426706B2 (en) | 2017-06-21 | 2022-08-30 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| WO2019060718A1 (en) * | 2017-09-22 | 2019-03-28 | Immunogen, Inc. | SEPARATION OF LIGHT TRIPLE CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| KR20200136464A (ko) * | 2018-03-29 | 2020-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단량체성 모노클로날 항체를 정제하는 방법 |
| CN112105927B (zh) * | 2018-05-08 | 2024-06-25 | 沃特世科技公司 | 可用于pH梯度阳离子交换色谱法的方法、组合物和试剂盒 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| SG11202101860UA (en) | 2018-08-31 | 2021-03-30 | Genzyme Corp | Sterile chromatography resin and use thereof in manufacturing processes |
| EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
| MA54052A (fr) | 2018-10-29 | 2022-02-09 | Hoffmann La Roche | Formulation d'anticorps |
| CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
| CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
| WO2021076489A1 (en) * | 2019-10-14 | 2021-04-22 | Pierce Biotechnology, Inc. | Peptide purification formulations and methods |
| AU2020377919A1 (en) * | 2019-11-07 | 2022-06-16 | Amgen Inc. | High salt washes during cation exchange chromatography to remove product-realated impurities |
| MX2022006330A (es) * | 2019-11-25 | 2022-08-17 | Akeso Biopharma Inc | Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo. |
| KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
| EP4130045A4 (en) * | 2020-03-25 | 2023-12-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE |
| IL299376A (en) | 2020-06-29 | 2023-02-01 | Genentech Inc | Fixed dose combination of pertuzumab plus transtuzumab |
| US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
| TW202337494A (zh) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物 |
| CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
| AU2023367498A1 (en) | 2022-10-26 | 2025-05-22 | Nihon Medi-Physics Co., Ltd. | Method for producing radioactive pharmaceutical composition |
| CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
| CN117756878A (zh) * | 2023-12-26 | 2024-03-26 | 康日百奥生物科技(苏州)有限公司 | 抗体层析分离方法及应用 |
| WO2025193804A1 (en) * | 2024-03-12 | 2025-09-18 | Massachusetts Eye And Ear Infirmary | Methods and materials for treating ocular neovascular diseases |
| WO2025232755A1 (zh) * | 2024-05-07 | 2025-11-13 | 南京蓬勃生物科技有限公司 | 一种使用阳离子交换层析纯化目标蛋白的方法 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
| WO1984002129A1 (fr) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Proteine de l'interferon immun humain et son procede de preparation |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| WO1986002068A1 (fr) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Separation mutuelle de proteines |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| CA1283072C (en) | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5451662A (en) * | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
| US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
| US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
| JP2749167B2 (ja) | 1988-06-21 | 1998-05-13 | ジェネンテク，インコーポレイテッド | 心筋梗塞の処置のための方法および治療用組成物 |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5112951A (en) * | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
| US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
| EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| DK0602126T3 (da) | 1991-08-14 | 2003-06-16 | Genentech Inc | Immunoglobulinvarianter til specifikke FC epsilon-receptorer |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| JPH08500826A (ja) | 1992-08-21 | 1996-01-30 | ジェネンテク，インコーポレイテッド | Ｌｆａ−１仲介疾患を処置する方法 |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ES2108566T3 (es) | 1993-12-10 | 1997-12-16 | Genentech Inc | Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos. |
| AP660A (en) | 1994-01-18 | 1998-08-18 | Genentech Inc | A method of treatment of parasitic infection using IgE antagonists. |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| JP3780315B2 (ja) | 1994-03-03 | 2006-05-31 | ジェネンテク・インコーポレイテッド | 炎症性疾患の処置のための抗ｉｌ−８モノクローナル抗体 |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2242414C (en) | 1996-01-23 | 2012-01-03 | Genentech, Inc. | Anti-cd18 antibodies for use against stroke |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| CN1268639C (zh) * | 1996-11-15 | 2006-08-09 | 基因技术股份有限公司 | 神经营养蛋白的纯化 |
| KR100532178B1 (ko) | 1996-11-27 | 2005-12-01 | 제넨테크, 인크. | 인간화 항-ＣＤ11ａ 항체 |
| ES2293661T3 (es) | 1996-11-27 | 2008-03-16 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteinas a. |
| PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN100480269C (zh) | 1997-04-07 | 2009-04-22 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| JP2001511653A (ja) | 1997-05-15 | 2001-08-14 | ジェネンテク，インコーポレイテッド | Ａｐｏ−２レセプター |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| KR101036414B1 (ko) * | 1998-05-06 | 2011-05-23 | 제넨테크, 인크. | 이온 교환 크로마토그래피에 의한 단백질 정제 방법 |
| ATE274522T1 (de) | 1998-06-01 | 2004-09-15 | Genentech Inc | Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie |
| AU753468B2 (en) | 1998-06-09 | 2002-10-17 | Csl Behring Ag | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| AU784045B2 (en) | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| NZ518477A (en) | 1999-10-29 | 2004-10-29 | Genentech Inc | Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| US6417355B1 (en) * | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
| EP1507793A4 (en) | 2001-10-17 | 2006-02-01 | Human Genome Sciences Inc | NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20060182740A1 (en) * | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| WO2004024866A2 (en) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Protein purification |
| ES2524694T3 (es) | 2002-10-17 | 2014-12-11 | Genmab A/S | Anticuerpos monoclonales humanos contra CD20 |
| AU2003287131B2 (en) | 2002-12-13 | 2008-07-24 | Mitra Medical Technology Ab | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| RS20100366A (sr) | 2002-12-16 | 2011-04-30 | Genentech, Inc. | Varijante imunoglobulina i njihova upotreba |
| MXPA05007182A (es) | 2002-12-31 | 2006-04-07 | Altus Pharmaceuticals Inc | Complejos de cristales de proteina y polimeros ionicos. |
| US20060257972A1 (en) * | 2003-03-31 | 2006-11-16 | Takashi Ishihara | Purification of human monoclonal antibody and human polyclonal antibody |
| KR101351122B1 (ko) | 2003-05-09 | 2014-01-14 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| AU2004263538B2 (en) | 2003-08-08 | 2009-09-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
| TW200533357A (en) † | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
| AR049021A1 (es) * | 2004-04-16 | 2006-06-21 | Genentech Inc | Tratamiento de trastornos con un anticuerpo que se une a cd20 |
| EP1833970A2 (en) * | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| HUE049797T2 (hu) * | 2005-03-11 | 2020-10-28 | Wyeth Llc | Gyenge megoszlási kromatográfiás eljárás |
| EP1896504B1 (en) * | 2005-06-17 | 2012-11-21 | Wyeth LLC | Methods of purifying fc region containing antibodies |
| WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
| CN101437839A (zh) * | 2006-03-20 | 2009-05-20 | 米德列斯公司 | 蛋白质纯化 |
| TWI392684B (zh) * | 2006-04-05 | 2013-04-11 | 亞培生物科技公司 | 抗體之純化 |
| KR101770312B1 (ko) * | 2006-08-28 | 2017-08-22 | 아레스 트레이딩 에스.에이. | Ｆｃ함유 단백질을 정제하는 방법 |
| US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| US20100209434A1 (en) * | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| PL2840090T3 (pl) * | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
| WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en not_active Ceased
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active Active
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Ceased
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Ceased
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02101B (me) | Pročišćavanje antitijela hromatografijom izmjene katjona | |
| HRP20171095T4 (hr) | Postupci pročišćavanja polipeptida | |
| US10053489B2 (en) | Method for purifying antibody | |
| CA2923133C (en) | Methods of cleaning a protein a based affinity chromatography column | |
| HRP20190485T4 (hr) | Kromatografija preopterećenja i elucijska kromatografija | |
| JP2014532718A5 (me) | ||
| JP7678863B2 (ja) | クロマトグラフィーにおけるバイオバーデンを低減するための組成物および方法 | |
| HRP20201118T1 (hr) | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije | |
| JP2018510867A5 (me) | ||
| ES2670827T3 (es) | Proceso para la purificación del factor estimulador de colonias de granulocitos, G-CSF | |
| JP5944101B2 (ja) | 非グリコシル化タンパク質の精製 | |
| JP2015520667A (ja) | クロマトグラフィー法 | |
| JP2014507368A5 (me) | ||
| RU2014121886A (ru) | Устройство для обработки курительного изделия и картридж для него | |
| CN103275217A (zh) | 磁珠法快速纯化抗体 | |
| FI3395423T3 (fi) | Vuotaneen affiniteettipuhdistusligandin poistaminen | |
| JP2025090586A (ja) | クロマトグラフィーの使用および再生のためのシステムおよび方法 | |
| Westra et al. | Immobilised metal-ion affinity chromatography purification of histidine-tagged recombinant proteins: a wash step with a low concentration of EDTA | |
| CN105837687A (zh) | 一种抗TNF-α类单克隆抗体的层析方法 | |
| DE10155984A1 (de) | Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices | |
| KR20220101168A (ko) | 이온 교환 크로마토그래피 동안 항체의 수율을 증가시키는 방법 | |
| CN116425826A (zh) | 一种快速纯化质量样品的方法 | |
| TH104746A (th) | การทำให้บริสุทธิ์ของแอนตี้บอดี้โดยการโครมาโตกราฟีแบบแลกเปลี่ยนประจุบวก | |
| TH74141B (th) | การผลิตแบบรีคอมบิแนนท์ของโปรตีนที่ยึดเหนี่ยวเฮปปาริน | |
| TH89903A (th) | การผลิตแบบรีคอมบิแนนท์ของโปรตีนที่ยึดเหนี่ยวเฮปปาริน |